Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019028427) METHODS FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS FOR ACTIVATING TIE2 RECEPTOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/028427 International Application No.: PCT/US2018/045267
Publication Date: 07.02.2019 International Filing Date: 03.08.2018
IPC:
A61K 38/00 (2006.01) ,A61K 38/16 (2006.01) ,A61K 38/10 (2006.01) ,A61K 39/395 (2006.01) ,C12N 5/00 (2006.01) ,C12N 15/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10
Peptides having 12 to 20 amino acids
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Applicants:
ASCLEPIX THERAPEUTICS, LLC. [US/US]; 301 West 29th Street Suite 204 Baltimore, MD 21211, US
THE JOHNS HOPKINS UNIVERSITY [US/US]; 3400 North Charles Street Baltimore, MD 21218, US
Inventors:
PANDEY, Niranjan B.; US
POPEL, Aleksander S.; US
GREEN, Jordan J.; US
MIRANDO, Adam; US
Agent:
HAYMAN, Mark L.; US
LIN, Yi-chia; US
ALTIERI, Stephen; US
CURRIE, Matthew, T.; US
FRANK, Steven, J.; US
Priority Data:
62/540,88003.08.2017US
Title (EN) METHODS FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS FOR ACTIVATING TIE2 RECEPTOR
(FR) PROCÉDÉS D'IDENTIFICATION ET DE PRÉPARATION D'AGENTS PHARMACEUTIQUES POUR ACTIVER LE RÉCEPTEUR TIE2
Abstract:
(EN) The present invention in various aspects and embodiments involves pharmaceutical compositions prepared by contacting a candidate a- or β-integrin-binding molecule, or panel thereof, with an integrin heterodimer, and quantifying heterodimer disruption by the candidate molecule. An integrin-binding molecule, or derivative thereof, that disrupts the integrin heterodimer is selected and is formulated into a pharmaceutical composition for administration to a subject, e.g., who has a disease or disorder related to abnormal vascularization.
(FR) La présente invention concerne, dans divers aspects et modes de réalisation, des compositions pharmaceutiques préparées par la mise en contact d'une molécule de liaison à l’intégrine α ou β candidate, ou d'un panel de celle-ci, avec un hétérodimère d'intégrine, et la quantification d'une rupture d'hétérodimère par la molécule candidate. Une molécule de liaison à l'intégrine, ou un dérivé de celle-ci, qui rompt l'hétérodimère d'intégrine, est sélectionnée et est formulée en une composition pharmaceutique destinée à être administrée à un sujet, par exemple un sujet souffrant d’une maladie ou d’un trouble liés à une vascularisation anormale.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)